What is the impact of stromal microinvasion on oncologic outcomes in borderline ovarian tumors? A multicenter case–control study
Purpose To investigate clinicopathological characteristics and oncological outcome of women with microinvasive BOTs. Methods A retrospective multicenter case–control study was conducted on 902 patients with BOT, who underwent surgery from January 2002 to December 2015 at six participating gynecologi...
Gespeichert in:
| Veröffentlicht in: | Archives of gynecology and obstetrics 2017-11, Vol.296 (5), p.979-987 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 987 |
|---|---|
| container_issue | 5 |
| container_start_page | 979 |
| container_title | Archives of gynecology and obstetrics |
| container_volume | 296 |
| creator | Boyraz, Gokhan Salman, Mehmet Coskun Gultekin, Murat Ozkan, Nazlı Topfedaisi Uckan, Hasan H. Gungorduk, Kemal Gulseren, Varol Ayik, Hulya Toptas, Tayfun Kuru, Oguzhan Sozen, Hamdullah Erturk, Anıl Ozgul, Nejat Meydanlı, Mehmet Mutlu Sanci, Muzaffer Turan, Taner Gungor, Tayfun Simsek, Tayup Topuz, Samet Yuce, Kunter |
| description | Purpose
To investigate clinicopathological characteristics and oncological outcome of women with microinvasive BOTs.
Methods
A retrospective multicenter case–control study was conducted on 902 patients with BOT, who underwent surgery from January 2002 to December 2015 at six participating gynecologic oncology centers from Turkey. Among 902 patients, 69 had microinvasive BOT. For every patient with microinvasive BOT, two controls were randomly selected from another database based on decade of age and stage of disease at diagnosis. The clinical–pathological characteristics and oncological outcomes were compared between BOT patients with and without stromal microinvasion. Risk factors for poor oncological outcomes were investigated in a multivariate analysis model. Overall survival (OS) and disease-free survival (DFS) were estimated using the Kaplan–Meier method.
Results
Patients with microinvasive BOT had a significantly higher rate of recurrence than patients without microinvasive BOT (17.4 vs 7.8%, OR 3.55, %95 CI 1.091–11.59,
p
= 0.03). Stage at diagnosis (stage I versus II/III) and type of surgery (cystectomy versus others) were found as other significant prognostic factors for recurrence in multivariate analysis (OR 8.63, %95 CI 2.48–29.9,
p
= 0.001 and OR 19.4, %95 CI 3.59–105.6,
p
= 0.001, respectively). Stromal microinvasion was found as a prognostic factor for significantly shorter DFS (26.7 vs 11.9 months,
p
= 0.031, log rank). However, there was no significant difference in OS between two groups (
p
= 0.99, log rank).
Conclusion
Stromal microinvasion is significantly associated with decreased DFS. In addition, our study confirms that the risk of recurrence is higher in patients with microinvasive BOT. |
| doi_str_mv | 10.1007/s00404-017-4496-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1935402870</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2261531441</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-59f699ef6aab2511574b7590a66f788b1f2dc6cbcbc52f94b675a520942f1baf3</originalsourceid><addsrcrecordid>eNp1kc9qFTEUxoMo9lp9ADcScONmNCeTP5OVlFKrUHCjuAyZ3KRNmSTXJFPoTnwF39Anaa63KgiSwAmc3_m-cD6EngN5DYTIN5UQRthAQA6MKTGwB2gDbKQDkQAP0Yao_ZsIeYSe1HpNCNBpEo_R0b4IOY0b9P3LlWk4VNyuHA5xZ2zD2ePaSo5mwTHYkkO6MTXkhH9dm5d8GSzOa7M5uopDwnMuW1eWkBzON6YEk3BbYy71LT7BcV1asC41V7A11f389sPm1A2WbrNub5-iR94s1T27r8fo87uzT6fvh4uP5x9OTy4GO0raBq68UMp5YcxMOQCXbJZcESOEl9M0g6dbK-zcD6desVlIbjglilEPs_HjMXp10N2V_HV1tekYqnXLYpLLa9WgRs4InSTp6Mt_0Ou8ltR_pykVwEdgDDoFB6rvqNbivN6VEE251UD0PiB9CEj3gPQ-IM36zIt75XWObvtn4nciHaAHoPZWunTlr_X_Ve8ALz6eRw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2261531441</pqid></control><display><type>article</type><title>What is the impact of stromal microinvasion on oncologic outcomes in borderline ovarian tumors? A multicenter case–control study</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Boyraz, Gokhan ; Salman, Mehmet Coskun ; Gultekin, Murat ; Ozkan, Nazlı Topfedaisi ; Uckan, Hasan H. ; Gungorduk, Kemal ; Gulseren, Varol ; Ayik, Hulya ; Toptas, Tayfun ; Kuru, Oguzhan ; Sozen, Hamdullah ; Erturk, Anıl ; Ozgul, Nejat ; Meydanlı, Mehmet Mutlu ; Sanci, Muzaffer ; Turan, Taner ; Gungor, Tayfun ; Simsek, Tayup ; Topuz, Samet ; Yuce, Kunter</creator><creatorcontrib>Boyraz, Gokhan ; Salman, Mehmet Coskun ; Gultekin, Murat ; Ozkan, Nazlı Topfedaisi ; Uckan, Hasan H. ; Gungorduk, Kemal ; Gulseren, Varol ; Ayik, Hulya ; Toptas, Tayfun ; Kuru, Oguzhan ; Sozen, Hamdullah ; Erturk, Anıl ; Ozgul, Nejat ; Meydanlı, Mehmet Mutlu ; Sanci, Muzaffer ; Turan, Taner ; Gungor, Tayfun ; Simsek, Tayup ; Topuz, Samet ; Yuce, Kunter</creatorcontrib><description>Purpose
To investigate clinicopathological characteristics and oncological outcome of women with microinvasive BOTs.
Methods
A retrospective multicenter case–control study was conducted on 902 patients with BOT, who underwent surgery from January 2002 to December 2015 at six participating gynecologic oncology centers from Turkey. Among 902 patients, 69 had microinvasive BOT. For every patient with microinvasive BOT, two controls were randomly selected from another database based on decade of age and stage of disease at diagnosis. The clinical–pathological characteristics and oncological outcomes were compared between BOT patients with and without stromal microinvasion. Risk factors for poor oncological outcomes were investigated in a multivariate analysis model. Overall survival (OS) and disease-free survival (DFS) were estimated using the Kaplan–Meier method.
Results
Patients with microinvasive BOT had a significantly higher rate of recurrence than patients without microinvasive BOT (17.4 vs 7.8%, OR 3.55, %95 CI 1.091–11.59,
p
= 0.03). Stage at diagnosis (stage I versus II/III) and type of surgery (cystectomy versus others) were found as other significant prognostic factors for recurrence in multivariate analysis (OR 8.63, %95 CI 2.48–29.9,
p
= 0.001 and OR 19.4, %95 CI 3.59–105.6,
p
= 0.001, respectively). Stromal microinvasion was found as a prognostic factor for significantly shorter DFS (26.7 vs 11.9 months,
p
= 0.031, log rank). However, there was no significant difference in OS between two groups (
p
= 0.99, log rank).
Conclusion
Stromal microinvasion is significantly associated with decreased DFS. In addition, our study confirms that the risk of recurrence is higher in patients with microinvasive BOT.</description><identifier>ISSN: 0932-0067</identifier><identifier>EISSN: 1432-0711</identifier><identifier>DOI: 10.1007/s00404-017-4496-4</identifier><identifier>PMID: 28866783</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adult ; Aged, 80 and over ; Case-Control Studies ; Disease-Free Survival ; Endocrinology ; Female ; Gynecologic Oncology ; Gynecology ; Human Genetics ; Humans ; Medical prognosis ; Medicine ; Medicine & Public Health ; Middle Aged ; Multivariate analysis ; Neoplasm Invasiveness - pathology ; Neoplasm Recurrence, Local - pathology ; Neoplasm Staging ; Obstetrics/Perinatology/Midwifery ; Ovarian cancer ; Ovarian Neoplasms - mortality ; Ovarian Neoplasms - pathology ; Ovarian Neoplasms - therapy ; Retrospective Studies ; Risk Factors ; Survival Rate ; Time Factors ; Turkey - epidemiology</subject><ispartof>Archives of gynecology and obstetrics, 2017-11, Vol.296 (5), p.979-987</ispartof><rights>Springer-Verlag GmbH Germany 2017</rights><rights>Archives of Gynecology and Obstetrics is a copyright of Springer, (2017). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-59f699ef6aab2511574b7590a66f788b1f2dc6cbcbc52f94b675a520942f1baf3</citedby><cites>FETCH-LOGICAL-c372t-59f699ef6aab2511574b7590a66f788b1f2dc6cbcbc52f94b675a520942f1baf3</cites><orcidid>0000-0002-4221-4459 ; 0000-0001-8120-1143 ; 0000-0003-1504-1756 ; 0000-0002-3028-7247 ; 0000-0001-7768-8278 ; 0000-0003-1088-3970 ; 0000-0002-4257-9731 ; 0000-0002-6706-6915 ; 0000-0001-6165-1497</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00404-017-4496-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00404-017-4496-4$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28866783$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Boyraz, Gokhan</creatorcontrib><creatorcontrib>Salman, Mehmet Coskun</creatorcontrib><creatorcontrib>Gultekin, Murat</creatorcontrib><creatorcontrib>Ozkan, Nazlı Topfedaisi</creatorcontrib><creatorcontrib>Uckan, Hasan H.</creatorcontrib><creatorcontrib>Gungorduk, Kemal</creatorcontrib><creatorcontrib>Gulseren, Varol</creatorcontrib><creatorcontrib>Ayik, Hulya</creatorcontrib><creatorcontrib>Toptas, Tayfun</creatorcontrib><creatorcontrib>Kuru, Oguzhan</creatorcontrib><creatorcontrib>Sozen, Hamdullah</creatorcontrib><creatorcontrib>Erturk, Anıl</creatorcontrib><creatorcontrib>Ozgul, Nejat</creatorcontrib><creatorcontrib>Meydanlı, Mehmet Mutlu</creatorcontrib><creatorcontrib>Sanci, Muzaffer</creatorcontrib><creatorcontrib>Turan, Taner</creatorcontrib><creatorcontrib>Gungor, Tayfun</creatorcontrib><creatorcontrib>Simsek, Tayup</creatorcontrib><creatorcontrib>Topuz, Samet</creatorcontrib><creatorcontrib>Yuce, Kunter</creatorcontrib><title>What is the impact of stromal microinvasion on oncologic outcomes in borderline ovarian tumors? A multicenter case–control study</title><title>Archives of gynecology and obstetrics</title><addtitle>Arch Gynecol Obstet</addtitle><addtitle>Arch Gynecol Obstet</addtitle><description>Purpose
To investigate clinicopathological characteristics and oncological outcome of women with microinvasive BOTs.
Methods
A retrospective multicenter case–control study was conducted on 902 patients with BOT, who underwent surgery from January 2002 to December 2015 at six participating gynecologic oncology centers from Turkey. Among 902 patients, 69 had microinvasive BOT. For every patient with microinvasive BOT, two controls were randomly selected from another database based on decade of age and stage of disease at diagnosis. The clinical–pathological characteristics and oncological outcomes were compared between BOT patients with and without stromal microinvasion. Risk factors for poor oncological outcomes were investigated in a multivariate analysis model. Overall survival (OS) and disease-free survival (DFS) were estimated using the Kaplan–Meier method.
Results
Patients with microinvasive BOT had a significantly higher rate of recurrence than patients without microinvasive BOT (17.4 vs 7.8%, OR 3.55, %95 CI 1.091–11.59,
p
= 0.03). Stage at diagnosis (stage I versus II/III) and type of surgery (cystectomy versus others) were found as other significant prognostic factors for recurrence in multivariate analysis (OR 8.63, %95 CI 2.48–29.9,
p
= 0.001 and OR 19.4, %95 CI 3.59–105.6,
p
= 0.001, respectively). Stromal microinvasion was found as a prognostic factor for significantly shorter DFS (26.7 vs 11.9 months,
p
= 0.031, log rank). However, there was no significant difference in OS between two groups (
p
= 0.99, log rank).
Conclusion
Stromal microinvasion is significantly associated with decreased DFS. In addition, our study confirms that the risk of recurrence is higher in patients with microinvasive BOT.</description><subject>Adult</subject><subject>Aged, 80 and over</subject><subject>Case-Control Studies</subject><subject>Disease-Free Survival</subject><subject>Endocrinology</subject><subject>Female</subject><subject>Gynecologic Oncology</subject><subject>Gynecology</subject><subject>Human Genetics</subject><subject>Humans</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Multivariate analysis</subject><subject>Neoplasm Invasiveness - pathology</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Neoplasm Staging</subject><subject>Obstetrics/Perinatology/Midwifery</subject><subject>Ovarian cancer</subject><subject>Ovarian Neoplasms - mortality</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Ovarian Neoplasms - therapy</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Survival Rate</subject><subject>Time Factors</subject><subject>Turkey - epidemiology</subject><issn>0932-0067</issn><issn>1432-0711</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kc9qFTEUxoMo9lp9ADcScONmNCeTP5OVlFKrUHCjuAyZ3KRNmSTXJFPoTnwF39Anaa63KgiSwAmc3_m-cD6EngN5DYTIN5UQRthAQA6MKTGwB2gDbKQDkQAP0Yao_ZsIeYSe1HpNCNBpEo_R0b4IOY0b9P3LlWk4VNyuHA5xZ2zD2ePaSo5mwTHYkkO6MTXkhH9dm5d8GSzOa7M5uopDwnMuW1eWkBzON6YEk3BbYy71LT7BcV1asC41V7A11f389sPm1A2WbrNub5-iR94s1T27r8fo87uzT6fvh4uP5x9OTy4GO0raBq68UMp5YcxMOQCXbJZcESOEl9M0g6dbK-zcD6desVlIbjglilEPs_HjMXp10N2V_HV1tekYqnXLYpLLa9WgRs4InSTp6Mt_0Ou8ltR_pykVwEdgDDoFB6rvqNbivN6VEE251UD0PiB9CEj3gPQ-IM36zIt75XWObvtn4nciHaAHoPZWunTlr_X_Ve8ALz6eRw</recordid><startdate>20171101</startdate><enddate>20171101</enddate><creator>Boyraz, Gokhan</creator><creator>Salman, Mehmet Coskun</creator><creator>Gultekin, Murat</creator><creator>Ozkan, Nazlı Topfedaisi</creator><creator>Uckan, Hasan H.</creator><creator>Gungorduk, Kemal</creator><creator>Gulseren, Varol</creator><creator>Ayik, Hulya</creator><creator>Toptas, Tayfun</creator><creator>Kuru, Oguzhan</creator><creator>Sozen, Hamdullah</creator><creator>Erturk, Anıl</creator><creator>Ozgul, Nejat</creator><creator>Meydanlı, Mehmet Mutlu</creator><creator>Sanci, Muzaffer</creator><creator>Turan, Taner</creator><creator>Gungor, Tayfun</creator><creator>Simsek, Tayup</creator><creator>Topuz, Samet</creator><creator>Yuce, Kunter</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4221-4459</orcidid><orcidid>https://orcid.org/0000-0001-8120-1143</orcidid><orcidid>https://orcid.org/0000-0003-1504-1756</orcidid><orcidid>https://orcid.org/0000-0002-3028-7247</orcidid><orcidid>https://orcid.org/0000-0001-7768-8278</orcidid><orcidid>https://orcid.org/0000-0003-1088-3970</orcidid><orcidid>https://orcid.org/0000-0002-4257-9731</orcidid><orcidid>https://orcid.org/0000-0002-6706-6915</orcidid><orcidid>https://orcid.org/0000-0001-6165-1497</orcidid></search><sort><creationdate>20171101</creationdate><title>What is the impact of stromal microinvasion on oncologic outcomes in borderline ovarian tumors? A multicenter case–control study</title><author>Boyraz, Gokhan ; Salman, Mehmet Coskun ; Gultekin, Murat ; Ozkan, Nazlı Topfedaisi ; Uckan, Hasan H. ; Gungorduk, Kemal ; Gulseren, Varol ; Ayik, Hulya ; Toptas, Tayfun ; Kuru, Oguzhan ; Sozen, Hamdullah ; Erturk, Anıl ; Ozgul, Nejat ; Meydanlı, Mehmet Mutlu ; Sanci, Muzaffer ; Turan, Taner ; Gungor, Tayfun ; Simsek, Tayup ; Topuz, Samet ; Yuce, Kunter</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-59f699ef6aab2511574b7590a66f788b1f2dc6cbcbc52f94b675a520942f1baf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Aged, 80 and over</topic><topic>Case-Control Studies</topic><topic>Disease-Free Survival</topic><topic>Endocrinology</topic><topic>Female</topic><topic>Gynecologic Oncology</topic><topic>Gynecology</topic><topic>Human Genetics</topic><topic>Humans</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Multivariate analysis</topic><topic>Neoplasm Invasiveness - pathology</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Neoplasm Staging</topic><topic>Obstetrics/Perinatology/Midwifery</topic><topic>Ovarian cancer</topic><topic>Ovarian Neoplasms - mortality</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Ovarian Neoplasms - therapy</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Survival Rate</topic><topic>Time Factors</topic><topic>Turkey - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Boyraz, Gokhan</creatorcontrib><creatorcontrib>Salman, Mehmet Coskun</creatorcontrib><creatorcontrib>Gultekin, Murat</creatorcontrib><creatorcontrib>Ozkan, Nazlı Topfedaisi</creatorcontrib><creatorcontrib>Uckan, Hasan H.</creatorcontrib><creatorcontrib>Gungorduk, Kemal</creatorcontrib><creatorcontrib>Gulseren, Varol</creatorcontrib><creatorcontrib>Ayik, Hulya</creatorcontrib><creatorcontrib>Toptas, Tayfun</creatorcontrib><creatorcontrib>Kuru, Oguzhan</creatorcontrib><creatorcontrib>Sozen, Hamdullah</creatorcontrib><creatorcontrib>Erturk, Anıl</creatorcontrib><creatorcontrib>Ozgul, Nejat</creatorcontrib><creatorcontrib>Meydanlı, Mehmet Mutlu</creatorcontrib><creatorcontrib>Sanci, Muzaffer</creatorcontrib><creatorcontrib>Turan, Taner</creatorcontrib><creatorcontrib>Gungor, Tayfun</creatorcontrib><creatorcontrib>Simsek, Tayup</creatorcontrib><creatorcontrib>Topuz, Samet</creatorcontrib><creatorcontrib>Yuce, Kunter</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Archives of gynecology and obstetrics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Boyraz, Gokhan</au><au>Salman, Mehmet Coskun</au><au>Gultekin, Murat</au><au>Ozkan, Nazlı Topfedaisi</au><au>Uckan, Hasan H.</au><au>Gungorduk, Kemal</au><au>Gulseren, Varol</au><au>Ayik, Hulya</au><au>Toptas, Tayfun</au><au>Kuru, Oguzhan</au><au>Sozen, Hamdullah</au><au>Erturk, Anıl</au><au>Ozgul, Nejat</au><au>Meydanlı, Mehmet Mutlu</au><au>Sanci, Muzaffer</au><au>Turan, Taner</au><au>Gungor, Tayfun</au><au>Simsek, Tayup</au><au>Topuz, Samet</au><au>Yuce, Kunter</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>What is the impact of stromal microinvasion on oncologic outcomes in borderline ovarian tumors? A multicenter case–control study</atitle><jtitle>Archives of gynecology and obstetrics</jtitle><stitle>Arch Gynecol Obstet</stitle><addtitle>Arch Gynecol Obstet</addtitle><date>2017-11-01</date><risdate>2017</risdate><volume>296</volume><issue>5</issue><spage>979</spage><epage>987</epage><pages>979-987</pages><issn>0932-0067</issn><eissn>1432-0711</eissn><abstract>Purpose
To investigate clinicopathological characteristics and oncological outcome of women with microinvasive BOTs.
Methods
A retrospective multicenter case–control study was conducted on 902 patients with BOT, who underwent surgery from January 2002 to December 2015 at six participating gynecologic oncology centers from Turkey. Among 902 patients, 69 had microinvasive BOT. For every patient with microinvasive BOT, two controls were randomly selected from another database based on decade of age and stage of disease at diagnosis. The clinical–pathological characteristics and oncological outcomes were compared between BOT patients with and without stromal microinvasion. Risk factors for poor oncological outcomes were investigated in a multivariate analysis model. Overall survival (OS) and disease-free survival (DFS) were estimated using the Kaplan–Meier method.
Results
Patients with microinvasive BOT had a significantly higher rate of recurrence than patients without microinvasive BOT (17.4 vs 7.8%, OR 3.55, %95 CI 1.091–11.59,
p
= 0.03). Stage at diagnosis (stage I versus II/III) and type of surgery (cystectomy versus others) were found as other significant prognostic factors for recurrence in multivariate analysis (OR 8.63, %95 CI 2.48–29.9,
p
= 0.001 and OR 19.4, %95 CI 3.59–105.6,
p
= 0.001, respectively). Stromal microinvasion was found as a prognostic factor for significantly shorter DFS (26.7 vs 11.9 months,
p
= 0.031, log rank). However, there was no significant difference in OS between two groups (
p
= 0.99, log rank).
Conclusion
Stromal microinvasion is significantly associated with decreased DFS. In addition, our study confirms that the risk of recurrence is higher in patients with microinvasive BOT.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>28866783</pmid><doi>10.1007/s00404-017-4496-4</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-4221-4459</orcidid><orcidid>https://orcid.org/0000-0001-8120-1143</orcidid><orcidid>https://orcid.org/0000-0003-1504-1756</orcidid><orcidid>https://orcid.org/0000-0002-3028-7247</orcidid><orcidid>https://orcid.org/0000-0001-7768-8278</orcidid><orcidid>https://orcid.org/0000-0003-1088-3970</orcidid><orcidid>https://orcid.org/0000-0002-4257-9731</orcidid><orcidid>https://orcid.org/0000-0002-6706-6915</orcidid><orcidid>https://orcid.org/0000-0001-6165-1497</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0932-0067 |
| ispartof | Archives of gynecology and obstetrics, 2017-11, Vol.296 (5), p.979-987 |
| issn | 0932-0067 1432-0711 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1935402870 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Adult Aged, 80 and over Case-Control Studies Disease-Free Survival Endocrinology Female Gynecologic Oncology Gynecology Human Genetics Humans Medical prognosis Medicine Medicine & Public Health Middle Aged Multivariate analysis Neoplasm Invasiveness - pathology Neoplasm Recurrence, Local - pathology Neoplasm Staging Obstetrics/Perinatology/Midwifery Ovarian cancer Ovarian Neoplasms - mortality Ovarian Neoplasms - pathology Ovarian Neoplasms - therapy Retrospective Studies Risk Factors Survival Rate Time Factors Turkey - epidemiology |
| title | What is the impact of stromal microinvasion on oncologic outcomes in borderline ovarian tumors? A multicenter case–control study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T20%3A20%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=What%20is%20the%20impact%20of%20stromal%20microinvasion%20on%20oncologic%20outcomes%20in%20borderline%20ovarian%20tumors?%20A%20multicenter%20case%E2%80%93control%20study&rft.jtitle=Archives%20of%20gynecology%20and%20obstetrics&rft.au=Boyraz,%20Gokhan&rft.date=2017-11-01&rft.volume=296&rft.issue=5&rft.spage=979&rft.epage=987&rft.pages=979-987&rft.issn=0932-0067&rft.eissn=1432-0711&rft_id=info:doi/10.1007/s00404-017-4496-4&rft_dat=%3Cproquest_cross%3E2261531441%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2261531441&rft_id=info:pmid/28866783&rfr_iscdi=true |